FDA
-
-
-
-
-
-
-
Trevena Reports First Quarter 2024 Results and Provides Business Update
-
-
-
-
-
-
-
Trevena Reports Third Quarter 2023 Results and Provides Business Update
-
-
-
-
-
-
-
Trevena Announces Preliminary TRV045 Data from Two Proof-of-Concept Studies Evaluating S1PR Mechanism of Action and CNS Target Engagement
-
-
-
-
-
-
-
Trevena Announces Receipt of Milestone Payment From Partner in China Jiangsu Nhwa Pharmaceutical
-
-
-
-
-
-
-
Trevena (TRVN) Reports Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study
-
-
-
-
-
-
-
Trevena Announces Poster Presentations of TRV045 Nonclinical Epilepsy Data, and OLINVYK Clinical Neurocognitive and GI Data, at Recent Medical Meetings
-
-
-
-
-
-
-
Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

